Published in Cancer on February 01, 2006
Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol (2009) 4.07
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 3.62
Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol (2013) 2.47
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol (2008) 2.20
The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. Int J Clin Pract (2008) 1.69
Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes (2007) 1.49
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol (2009) 1.44
Effect of testosterone administration on liver fat in older men with mobility limitation: results from a randomized controlled trial. J Gerontol A Biol Sci Med Sci (2013) 1.44
Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol (2011) 1.41
Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends Endocrinol Metab (2010) 1.41
Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol (2009) 1.30
Association between hormones and metabolic syndrome in older Italian men. J Am Geriatr Soc (2006) 1.13
The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes (2010) 1.11
Psychosocial intervention effects on adaptation, disease course and biobehavioral processes in cancer. Brain Behav Immun (2012) 1.10
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol (2008) 1.08
Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis (2013) 0.99
Endocrinology of the aging male. Best Pract Res Clin Endocrinol Metab (2011) 0.99
New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. Int J Cell Biol (2013) 0.98
Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PLoS One (2015) 0.95
Deletion of the androgen receptor in adipose tissue in male mice elevates retinol binding protein 4 and reveals independent effects on visceral fat mass and on glucose homeostasis. Diabetes (2012) 0.95
Energetics in colorectal and prostate cancer. J Clin Oncol (2010) 0.95
Welcoming low testosterone as a cardiovascular risk factor. Int J Impot Res (2009) 0.94
Neuronal androgen receptor regulates insulin sensitivity via suppression of hypothalamic NF-κB-mediated PTP1B expression. Diabetes (2012) 0.92
Innovations in the systemic therapy of prostate cancer. Nat Rev Clin Oncol (2009) 0.91
The role of androgens in metabolism, obesity, and diabetes in males and females. Obesity (Silver Spring) (2015) 0.90
Dietary intervention in the management of prostate cancer. Curr Opin Urol (2007) 0.90
Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control. World J Urol (2012) 0.88
Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complications. Asian J Androl (2012) 0.87
Sex steroids and glucose metabolism. Asian J Androl (2014) 0.87
Estrogenic side effects of androgen deprivation therapy. Rev Urol (2007) 0.87
Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Asian J Androl (2013) 0.85
The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer. Adv Urol (2012) 0.84
The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. Nutrients (2014) 0.83
Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues. Indian J Urol (2009) 0.82
Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy. Am J Med (2010) 0.82
Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks. Asian J Androl (2011) 0.82
Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes (2014) 0.81
Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art. Cancer Manag Res (2010) 0.81
Age disrupts androgen receptor-modulated negative feedback in the gonadal axis in healthy men. Am J Physiol Endocrinol Metab (2010) 0.81
Leuprorelin depot injection: patient considerations in the management of prostatic cancer. Ther Clin Risk Manag (2008) 0.80
Fasting blood glucose and lipid profile alterations following twelve-month androgen deprivation therapy in men with prostate cancer. ScientificWorldJournal (2012) 0.80
Extranuclear Actions of the Androgen Receptor Enhance Glucose-Stimulated Insulin Secretion in the Male. Cell Metab (2016) 0.79
The effects of testosterone deprivation and supplementation on proteasomal and autophagy activity in the skeletal muscle of the male mouse: differential effects on high-androgen responder and low-androgen responder muscle groups. Endocrinology (2013) 0.79
Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer. Prostate Cancer (2011) 0.79
Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective. Asian J Androl (2012) 0.79
Dystroglycan patterns on the prostate of non-obese diabetic mice submitted to glycaemic control. Int J Exp Pathol (2009) 0.77
Intervening on the side effects of hormone-dependent cancer treatment: the role of strength training. J Aging Res (2011) 0.77
The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil. Int J Endocrinol (2014) 0.77
Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol (2015) 0.77
Diabetes and mortality in patients with prostate cancer: a meta-analysis. Springerplus (2016) 0.77
Reduced Cardiovascular Capacity and Resting Metabolic Rate in Men with Prostate Cancer Undergoing Androgen Deprivation: A Comprehensive Cross-Sectional Investigation. Adv Urol (2015) 0.76
Metformin effects on biochemical recurrence and metabolic signaling in the prostate. Prostate (2015) 0.76
High-dose isoflavones do not improve metabolic and inflammatory parameters in androgen-deprived men with prostate cancer. J Androl (2010) 0.76
Perpetuating effects of androgen deficiency on insulin resistance. Int J Obes (Lond) (2016) 0.76
Distinct roles of age and abdominal visceral fat in reducing androgen receptor-dependent negative feedback on LH secretion in healthy men. Andrology (2014) 0.75
Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer. Front Oncol (2015) 0.75
Prostate cancer: cardiovascular mortality and androgen deprivation. Nat Rev Urol (2009) 0.75
SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study. Rep Pract Oncol Radiother (2015) 0.75
Role of hormonal therapy for prostate cancer: perspective from Japanese experiences. Transl Androl Urol (2012) 0.75
Physical functioning for prostate health. Can Urol Assoc J (2014) 0.75
A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients. Prostate Cancer Prostatic Dis (2016) 0.75
Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy. Can Urol Assoc J (2016) 0.75
Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis. J Diabetes Investig (2016) 0.75
The effect of flutamide on the physical working capacity and activity of some of the key enzymes for the energy supply in adult rats. Asian J Androl (2016) 0.75
LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer. World J Urol (2016) 0.75
MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease. Eur J Endocrinol (2017) 0.75
Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy. World J Urol (2012) 0.75
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med (2005) 6.02
The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes (2003) 3.23
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol (2007) 3.23
Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol (2006) 3.09
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05
Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol (2004) 2.91
Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol (2008) 2.75
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis (2005) 2.55
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol (2011) 2.46
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin Endocrinol Metab (2007) 2.29
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res (2006) 2.15
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol (2010) 2.07
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med (2012) 2.00
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol (2008) 1.91
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer (2012) 1.87
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
Sex-based differences in pain perception and treatment. Pain Med (2009) 1.82
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer (2011) 1.80
Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program. Urology (2009) 1.80
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther (2006) 1.74
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol (2008) 1.71
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J Clin Endocrinol Metab (2009) 1.71
The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care (2005) 1.70
Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab (2007) 1.70
Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) (2002) 1.64
Sex-dependent metabolic, neuroendocrine, and cognitive responses to dietary energy restriction and excess. Endocrinology (2007) 1.59
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression. Prostate (2011) 1.58
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2008) 1.56
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. Prostate (2013) 1.52
Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res (2006) 1.50
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol (2009) 1.44
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol (2008) 1.42
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol (2007) 1.41
Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One (2010) 1.40
Preventive care in prostate cancer patients: following diagnosis and for five-year survivors. J Cancer Surviv (2011) 1.38
Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res (2004) 1.36
Endocrine effects of marijuana. J Clin Pharmacol (2002) 1.35
Quality of care for comorbid conditions during the transition to survivorship: differences between cancer survivors and noncancer controls. J Clin Oncol (2013) 1.32
Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab (2004) 1.32
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res (2004) 1.31
How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Cancer (2010) 1.30
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med (2012) 1.29
Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study. J Clin Endocrinol Metab (2004) 1.29
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer (2012) 1.28
Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol (2003) 1.27
The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. PLoS One (2007) 1.26
Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes (2007) 1.26
Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate (2010) 1.25
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol (2005) 1.25
Racial difference in lung function in African-American and White children: effect of anthropometric, socioeconomic, nutritional, and environmental factors. Am J Epidemiol (2004) 1.23
Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets. Am J Physiol Endocrinol Metab (2007) 1.22
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol (2005) 1.22
Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc (2007) 1.22
Klinefelter syndrome: expanding the phenotype and identifying new research directions. Genet Med (2003) 1.21
Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Anal Biochem (2004) 1.21
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer (2011) 1.20
Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol (2013) 1.19
Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res (2008) 1.18
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer (2009) 1.17
Sex hormones, insulin resistance, and diabetes mellitus among men with or at risk for HIV infection. J Acquir Immune Defic Syndr (2011) 1.17
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol (2005) 1.16
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 1.15
Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice. Support Care Cancer (2007) 1.14
Feasibility and value of PatientViewpoint: a web system for patient-reported outcomes assessment in clinical practice. Psychooncology (2012) 1.14
Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: multi-ethnic study of atherosclerosis. Diabetes Care (2009) 1.14
Impact of reduced meal frequency without caloric restriction on glucose regulation in healthy, normal-weight middle-aged men and women. Metabolism (2007) 1.13
Association between hormones and metabolic syndrome in older Italian men. J Am Geriatr Soc (2006) 1.13
Differentiation therapy. Curr Opin Pharmacol (2003) 1.11
Testicular cancer. J Natl Compr Canc Netw (2012) 1.11
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol (2007) 1.10
The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol (2007) 1.10
Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist (2013) 1.09
Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy. AIDS (2007) 1.09
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res (2010) 1.09
Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am (2007) 1.09
New drugs in prostate cancer. Curr Opin Urol (2006) 1.08
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer (2002) 1.08
Depressive symptoms, quality of life, and neuropsychological performance in HIV/AIDS: the impact of gender and injection drug use. J Neurovirol (2005) 1.08
Relevant content for a patient-reported outcomes questionnaire for use in oncology clinical practice: Putting doctors and patients on the same page. Qual Life Res (2010) 1.07
Longitudinal anthropometric changes in HIV-infected and HIV-uninfected men. J Acquir Immune Defic Syndr (2006) 1.07
Changes in the incidence and predictors of wasting syndrome related to human immunodeficiency virus infection, 1987-1999. Am J Epidemiol (2002) 1.07